Value investing message boards image Log on |  Join ($$) Stock market forums image VF "How To" Guide        Welcome, guest! Learn about guest access                       
ValueForum.com Home
• Related Discussion Forum Messages
As a ValueForum member, this section would contain SRPT message board posts where the ticker symbol SRPT has been mentioned by ValueForum members in posts. Learn more about guest access, and benefits of membership -- we hope you will consider joining ValueForum or trying out our service with a 24 hour trial pass.

• Latest SRPT SEC Filings

Filings Format Description Filing Date File/Film Number
8-K  Documents   Interactive Data Current report, items 1.01, 2.03, and 8.01
Acc-no: 0001564590-19-045957 (34 Act)  Size: 184 KB
2019-12-13 001-14895
191284600
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001209191-19-059953 Size: 7 KB
2019-12-10
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001209191-19-058217 Size: 36 KB
2019-11-26
D  Documents Notice of Exempt Offering of Securities, item 06b
Acc-no: 0000904454-19-000735 (33 Act)  Size: 15 KB
2019-11-25 021-354185
191246483
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001209191-19-057542 Size: 5 KB
2019-11-20
3  Documents Initial statement of beneficial ownership of securities
Acc-no: 0001209191-19-057540 Size: 3 KB
2019-11-20
S-3ASR  Documents Automatic shelf registration statement of securities of well-known seasoned issuers
Acc-no: 0001193125-19-292454 (33 Act)  Size: 375 KB
2019-11-14 333-234698
191221417
10-Q  Documents   Interactive Data Quarterly report [Sections 13 or 15(d)]
Acc-no: 0001564590-19-041709 (34 Act)  Size: 11 MB
2019-11-07 001-14895
191200209
8-K  Documents   Interactive Data Current report, items 7.01 and 9.01
Acc-no: 0001564590-19-036441 (34 Act)  Size: 7 MB
2019-10-04 001-14895
191137651
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001209191-19-049553 Size: 6 KB
2019-09-16
More SRPT SEC Filings


Related news from
Fri, 13 Dec 2019
21:11:52 +0000
Sarepta Rockets On Stunning Reversal For Previously Rejected Drug
Shares of Sarepta Therapeutics rocketed Friday after the biotech company's previously rejected Duchenne muscular dystrophy drug nabbed U.S. approval. SRPT stock soared at the close.
Fri, 13 Dec 2019
17:22:00 +0000
Sarepta’s surprise FDA approval for rare disease drug excites investors
The Food and Drug Administration’s out-of-the-blue approval of Sarepta Therapeutics’ second Duchenne muscular dystrophy drug sent the company’s stock soaring.
Fri, 13 Dec 2019
15:13:37 +0000
FDA approves Sarepta's muscular dystrophy drug
The FDA has approved a drug from Sarepta Therapeutics for muscular dystrophy that it had previously rejected. Yahoo Finance’s Ines Ferre joins The First Trade from the floor of the New York Stock Exchange to discuss the latest market action.
Fri, 13 Dec 2019
14:00:00 +0000
Sarepta Stock Is Spiking as FDA Reverses Course, Approving Drug
The approval came faster than expected. Shares fell in August after the Food and Drug Administration denied approval for Vyondys 53, a treatment for Duchenne Muscular Dystrophy.
Fri, 13 Dec 2019
13:55:48 +0000
Sarepta's Vyondys 53 Receives FDA Approval for DMD, Stock Up
Sarepta (SRPT) exon-53 skipping DMD drug, Vyondys 53, gets approval in the United States following a CRL in August.
Fri, 13 Dec 2019
13:30:10 +0000
Sarepta Therapeutics Announces $250 Million of Non-Dilutive Senior Secured Loan Financing
Sarepta Therapeutics, Inc. (SRPT), the leader in precision genetic medicine for rare diseases, announced today that it has entered into an agreement with funds managed by Pharmakon Advisors, LP, that provides Sarepta with up to $500 million of borrowing capacity in two tranches. Pharmakon Advisors, LP, is the investment manager of the BioPharma Credit funds including BioPharma Credit Investments V LP and BioPharma Credit PLC (BPCR.L), the only listed investor specialized in life sciences debt. Sarepta is at the forefront of precision genetic medicine, having built an impressive and competitive position in Duchenne muscular dystrophy (DMD) and more recently in gene therapies for Limb-girdle muscular dystrophy diseases (LGMD), Charcot-Marie-Tooth (CMT), MPS IIIA and other CNS-related disorders, totaling over 20 therapies in various stages of development.
Fri, 13 Dec 2019
13:10:02 +0000
The Daily Biotech Pulse: Second Time's The Charm For Sarepta, Pfizer's Xeljanz Snags Third Approval, NewLink Genetics Rejects Competing Offer
The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs on Dec. 12.) Allergan plc (NYSE: AGN ) Amgen, Inc. (NASDAQ: ...
Fri, 13 Dec 2019
09:36:00 +0000
Sarepta Therapeutics Surges on FDA Approval of Muscular Dystrophy Treatment
Shares soar after the biotech company receives fast-track approval for its injectable treatment for Duchenne muscular dystrophy.
Fri, 13 Dec 2019
02:28:51 +0000
In an about face, FDA approves Sarepta's 2nd Duchenne drug
The FDA unexpectedly reversed course Thursday, approving the second treatment developed by Sarepta Therapeutics for the rare disease Duchenne muscular dystrophy just a few months after rejecting the drug.
Thu, 12 Dec 2019
23:43:00 +0000
Sarepta stock surges more than 20% as FDA finally OKs muscular dystrophy drug
Sarepta Therapeutics Inc. shares surged in the extended session Thursday after the genetic medicine company said the Food and Drug Administration approved its muscular dystrophy treatment. Sarepta shares rallied 23% after hours before being halted, and were last up 28% after being unhalted. Shares closed the regular session down 1% at $100.47. The company said the FDA approved Vyondys 53 for the treatment of Duchenne muscular dystrophy. The company said Vyondys 53 will be priced similarly to its other DMD treatment Exondys 51, which has not had a price increase since 2016. Back in August, shares dropped after the FDA said it could not approve the drug on concerns about kidney toxicity. At Thursday's close, Sarepta shares were down 8% for the year.
Thu, 12 Dec 2019
23:19:20 +0000
Sarepta Therapeutics Announces FDA Approval of VYONDYS 53™ (golodirsen) Injection for the Treatment of Duchenne Muscular Dystrophy (DMD) in Patients Amenable to Skipping Exon 53
Sarepta Therapeutics, Inc. (SRPT), the leader in precision genetic medicine for rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has approved VYONDYS 53™ (golodirsen). VYONDYS 53 is an antisense oligonucleotide from Sarepta’s phosphorodiamidate morpholino oligomer (PMO) platform, indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients with a confirmed mutation amenable to exon 53 skipping. This indication is based on a statistically significant increase in dystrophin production in skeletal muscle observed in patients treated with VYONDYS 53, which is reasonably likely to predict clinical benefit for those patients who are exon 53 amenable.
Tue, 10 Dec 2019
14:21:12 +0000
Why Is Sarepta Therapeutics (SRPT) Up 17.2% Since Last Earnings Report?
Sarepta Therapeutics (SRPT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Tue, 10 Dec 2019
12:00:00 +0000
Biotech accelerator teams with investment firm for $210M fund raise
A New York investment firm has raised $210 million for startups coming out of Boston-based biotech accelerator Xontogeny. It announced its first investment Tuesday: a $17 million early-stage funding of a local rare-disease startup.
Fri, 06 Dec 2019
14:33:02 +0000
The Zacks Analyst Blog Highlights: uniQure, Sarepta Therapeutics, BioMarin Pharmaceutical and Sangamo Therapeutics
The Zacks Analyst Blog Highlights: uniQure, Sarepta Therapeutics, BioMarin Pharmaceutical and Sangamo Therapeutics
Thu, 05 Dec 2019
21:32:34 +0000
Astellas-Audentes Deal Likely to Ignite More Acquisitions
Companies with gene therapy capabilities are becoming more attractive to members of Big Pharma, who are eager to add the technology to their portfolios Continue reading...
Thu, 05 Dec 2019
15:12:08 +0000
4 Solid Gene Therapy Buyout Bets Post Audentes-Astellas Deal
Gene therapy continues to draw attention with the recent spate of deals and acquisitions. We list four stocks with promising candidates in their pipelines that make attractive acquisition targets.
Thu, 05 Dec 2019
01:33:31 +0000
Did Hedge Funds Drop The Ball On Sarepta Therapeutics Inc (SRPT) ?
Our extensive research has shown that imitating the smart money can generate significant returns for retail investors, which is why we track nearly 750 active prominent money managers and analyze their quarterly 13F filings. The stocks that are heavily bought by hedge funds historically outperformed the market, though there is no shortage of high profile […]
Tue, 03 Dec 2019
16:53:46 +0000
The Gene Therapy Names Moving On The Audentes Buyout Deal
Gene therapy company Audentes Therapeutics Inc (NASDAQ: BOLD ) announced a deal late Monday to be acquired by Japanese pharma company ASTELLAS PHARMA/ADR (OTC: ALPMY ) for $60 per share, representing a ...
Tue, 03 Dec 2019
15:19:32 +0000
Breakeven On The Horizon For Sarepta Therapeutics, Inc. (NASDAQ:SRPT)
Sarepta Therapeutics, Inc.'s (NASDAQ:SRPT): Sarepta Therapeutics, Inc. focuses on the discovery and development of...
Fri, 29 Nov 2019
23:00:10 +0000
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Sarepta Therapeutics, Inc. (SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on November 29, 2019, that were previously approved by the Compensation Committee of its Board of Directors under Sarepta’s 2014 Employment Commencement Incentive Plan, as a material inducement to employment to fourteen individuals hired by Sarepta in November 2019. The employees received, in the aggregate, options to purchase 19,535 shares of Sarepta's common stock, and in the aggregate, 9,875 restricted stock units (“RSUs”). The options have an exercise price of $112.49 per share, which is equal to the closing price of Sarepta's common stock on November 29, 2019 (the “Grant Date”).



"ValueForum is an active, private, online discussion community for stock & bond market investing. In discussion forums divided into finely grained topics, you will find sophisticated investors trading tips, research, and due diligence on value stocks, income investments, forex, market news, and more. Join in - trade ideas, strategies, current news, via our unique message bulletin boards, stock ratings system, and other online tools specifically geared toward our community."

Random member testimonial: "This is one of the brightest and most generous groups you will ever come across. While I firmly believe everyone has something to contribute to the collective wisdom, this is pretty much a left-brain group. Facts, evidence, and reasoned argument will earn you respect, even if some disagree with you." more testimonials »

Email / About | Privacy | Terms of Use | How To / FAQ | Msg Ticker | VF Home | My.vf | BDCs.vf | Energy.vf | REITs.vf | TA.vf
 
Nothing in ValueForum.com is intended to be investment advice, nor does it represent the opinion of, counsel
from, or recommendations by ValueForum.com. ©2003 - 2019, Powered in part by Ticker TechnologiesContact Us

Stock Market Investing Forum - Trading Tips & Research - Online Message Boards